Scripps Genomic Medicine

The R&D deal targets oncology and cardiovascular disease.

The study, which surveyed more than 2,000 people, found that the "results of a direct-to-consumer genomic risk test do not affect health-related behavior."

A survey primarily using Scripps employees and Navigenics test offering shows that 50 percent of DTC genomics test takers have concerns, but over 80 percent want to know risks even of non-preventable diseases.

"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."

Under terms of the alliance, a Sanofi-aventis Group subsidiary will fund each year up to three Discovery Innovation Grants intended to offer flexible financing for innovative research proposals from investigators at a division of Scripps Health.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.